What are the indications and contraindications for imiquimod 5% cream?

Imiquimod 5% Cream: Indications and Contraindications

Imiquimod 5% cream is FDA-approved for three specific indications: external genital/perianal warts, actinic keratosis (AK) on the face or scalp, and superficial basal cell carcinoma (sBCC). 1

FDA-Approved Indications

1. Actinic Keratosis (Face or Scalp)

• Licensed specifically for: Clinically typical, non-hyperkeratotic, non-hypertrophic AKs on the face or scalp in immunocompetent adults 2, 3
• When to use: When the size or number of lesions limits the efficacy and/or acceptability of cryotherapy, and other topical treatment options are contraindicated or less appropriate 2
• Dosing: Apply at night, wash off after 8 hours, 3 times per week for 4 weeks; can repeat for another 4 weeks if needed 2, 1
• Efficacy: Meta-analysis shows 50% complete clearance rate, with 76% maintaining clearance at 12 months (superior to cryotherapy and 5-FU) 2

2. Superficial Basal Cell Carcinoma

• Licensed for: Small superficial BCCs in immunocompetent adults 1
• Dosing: Apply 5 times per week for 6 weeks, wash off after 8 hours 1
• Important limitation: Not for nodular BCC—recent 2025 data shows only 77.8% tumor-free survival at 5 years with curettage plus imiquimod versus 98.2% with surgical excision for nodular BCC 4

3. External Genital/Perianal Warts

• Dosing: Apply 3 times per week until complete clearance or maximum 16 weeks 5, 6, 1
• Wash off: 6-10 hours after application 5, 6, 1
• Special precautions: Avoid sexual contact while cream is on skin; avoid vaginal application (considered internal use); uncircumcised males must retract foreskin and clean daily 1

Key Contraindications and Precautions

Absolute Contraindications (Based on Licensing)

• Hyperkeratotic or hypertrophic AKs 2
• Immunocompromised patients (not licensed for this population) 2
• Nodular or aggressive BCCs (only superficial BCCs are indicated) 1
• Internal application (vaginal, urethral, rectal mucosa) 1

Relative Contraindications and Warnings

• Pregnancy: Safety not established 5, 6
• Eyes, lips, nostrils: Must avoid contact 1
• Occlusion: Treatment area should NOT be bandaged or occluded 1
• Sun exposure: Minimize or avoid natural/artificial sunlight during treatment 1

Critical Safety Information

Expected Local Reactions (Very Common)

Counsel patients that local reactions are EXPECTED and normal:

• Erythema, edema, erosions/ulcerations, weeping, flaking/scaling, scabbing/crusting 1
• Itching and burning at application site 1
• Reactions may extend beyond application site 1
• Treatment area will appear noticeably different from normal skin during and after treatment 1
• Permanent hypopigmentation or hyperpigmentation may occur 1

Systemic Reactions (Common)

• Flu-like symptoms: malaise, fever, nausea, myalgias, rigors 1
• Management: Consider interruption of dosing if systemic symptoms occur 1

When to Stop or Pause Treatment

• Rest periods may be needed if local reactions are severe 1
• Resume after skin reaction subsides 1
• Contact physician if symptoms restrict daily activity or make application difficult 1
• Do NOT extend treatment beyond maximum duration (16 weeks for AK/warts, 6 weeks for sBCC) even for missed doses 1

Common Pitfalls to Avoid

1. Do not use for thick, hyperkeratotic lesions on face/scalp—these are specifically excluded from the license 2
2. Do not use as monotherapy for nodular BCC—only superficial BCCs are appropriate 4
3. Do not apply to mucous membranes or internal surfaces 1
4. Do not occlude the treatment area with bandages 1
5. Warn female patients about urinary retention risk if treating near vaginal opening due to local swelling 1
6. Discard partially-used packets—do not reuse 1

Off-Label Uses (Mentioned in Evidence)

While not FDA-approved, imiquimod has been studied for Bowen's disease, erythroplasia of Queyrat, and cervical intraepithelial neoplasia 7, 8, 9. However, these remain off-label and require careful patient selection and informed consent.